Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CAO Sells $3,424,031.80 in Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CAO Michael Megna sold 36,260 shares of the stock in a transaction on Friday, October 30th. The shares were sold at an average price of $94.43, for a total value of $3,424,031.80. Following the completion of the transaction, the chief accounting officer directly owned 12,697 shares in the company, valued at approximately $1,198,977.71. This represents a 74.06% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Stock Down 8.1%

NASDAQ KNSA opened at $88.34 on Friday. The stock’s 50-day simple moving average is $80.18 and its two-hundred day simple moving average is $61.10. Kiniksa Pharmaceuticals International, plc has a twelve month low of $37.02 and a twelve month high of $98.48. The company has a market capitalization of $6.89 billion, a price-to-earnings ratio of 67.95 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. The firm had revenue of $285.97 million during the quarter, compared to analysts’ expectations of $260.66 million. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. On average, equities analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.30 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Hedge funds and other institutional investors have recently modified their holdings of the stock. Rubric Capital Management LP boosted its position in Kiniksa Pharmaceuticals International by 12.7% during the 1st quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company’s stock valued at $180,562,000 after buying an additional 421,347 shares during the period. Pictet Asset Management Holding SA grew its holdings in Kiniksa Pharmaceuticals International by 41.3% in the 3rd quarter. Pictet Asset Management Holding SA now owns 860,228 shares of the company’s stock worth $64,182,000 after acquiring an additional 251,578 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Kiniksa Pharmaceuticals International by 18.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 811,922 shares of the company’s stock worth $39,086,000 after acquiring an additional 128,417 shares during the last quarter. Spruce Street Capital LP increased its position in shares of Kiniksa Pharmaceuticals International by 75.0% in the first quarter. Spruce Street Capital LP now owns 761,063 shares of the company’s stock valued at $36,645,000 after acquiring an additional 326,081 shares during the period. Finally, Bank of America Corp DE increased its position in shares of Kiniksa Pharmaceuticals International by 220.9% in the first quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock valued at $35,436,000 after acquiring an additional 506,576 shares during the period. Institutional investors own 53.95% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on KNSA shares. JPMorgan Chase & Co. increased their price target on shares of Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Wells Fargo & Company boosted their price objective on shares of Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, October 28th. Wedbush boosted their price objective on shares of Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the stock an “outperform” rating in a report on Wednesday, October 28th. Weiss Ratings cut shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Wednesday, October 28th. Finally, The Goldman Sachs Group increased their target price on shares of Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the company a “buy” rating in a report on Wednesday, October 28th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Kiniksa Pharmaceuticals International presently has an average rating of “Moderate Buy” and a consensus price target of $100.57.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.